Research programme: laminin-5 monoclonal antibodies - BioStratum/Novo Nordisk

Drug Profile

Research programme: laminin-5 monoclonal antibodies - BioStratum/Novo Nordisk

Alternative Names: BST-1005; gamma2-monoclonal antibody; γ2-MAb

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator BioStratum
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cancer metastases

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer-metastases in USA
  • 14 Jan 2004 Laminin-5 monoclonal antibodies have been licensed to Novo Nordisk worldwide for the treatment of cancer
  • 18 Jul 2003 Preclinical trials in Cancer metastases in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top